RGEN
Repligen CorporationHealthcare · $10.7B market cap
Verdict
Share price
$181.70
close of Oct 3, 2026
Fair value
$48.32
Sticker Price
Payback Price
$19.33
buy price
RGEN is Overpriced: at $181.70 it trades 276% above its fair value of $48.32. Its buy price (Payback Price) is $19.33, 89% below today's price. Business quality is strong: 4 of 5 key numbers clear the 10% bar.
How we valued it
Earnings Power. Our 10-year earnings projection came out at less than a fifth of the share price, too far from reality to publish. So we use a simpler measure: today's normal earnings at the price-to-earnings ratio it has typically traded at.
Business quality
4 of 5 clear the 10% bar. What are the Big Five?
Follow RGEN
Get notified when it reaches its buy price of $19.33. Free.
Create a free accountSuperinvestors
2 of the investors we track hold RGEN. In Q2 2026, 2 added and 1 sold out. Who we track
Insider activity
Since Mar 5, 2026: no open-market purchases, 4 sales worth $1.7M and 4 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Loeillot Olivier
Chief Executive Officer · 2026-09-04
Sold
$504K
Loeillot Olivier
Chief Executive Officer · 2026-08-20
Sold
$977K
Garland Jason K
CFO · 2026-07-16
Sold
$80K
Garland Jason K
CFO · 2026-06-25
Sold
$106K
Other filings
About Repligen Corporation
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses…
Medical - Instruments & Supplies
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works